Myriad Genetics Buys Genetic Marker Technology

Salt Lake City-based Myriad Genetics said this week that it has signed an agreement to acquire proprietary technology from California-based Melanoma Diagnostics, used for the diagnosis and prognosis of malignant melanoma. Financial details of the deal were not announced. Myriad said Melanoma Diagnostics develops technology which uses genetic markers for testing and early detection of melanoma. The deal includes upfront fees and contingent payments for the technology.